Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

This article was originally published in The Pink Sheet Daily

Executive Summary

Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.

You may also be interested in...

India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors

MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country

GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 1 Of 2)

Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts